Finerenone in the management of diabetes kidney disease
Abstract People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardio...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-025-03985-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825197645324353536 |
|---|---|
| author | Parijat De May T Khine Andrew Frankel Gabrielle Goldet Debasish Banerjee Rosa M Montero Tahseen A Chowdhury Damien Fogarty Janaka Karalliedde Ritwika Mallik Dipesh C Patel Mona Wahba Peter Winocour Sagen Zac-Varghese Stephen Bain Adnan Sharif Srikanth Bellary Indranil Dasgupta |
| author_facet | Parijat De May T Khine Andrew Frankel Gabrielle Goldet Debasish Banerjee Rosa M Montero Tahseen A Chowdhury Damien Fogarty Janaka Karalliedde Ritwika Mallik Dipesh C Patel Mona Wahba Peter Winocour Sagen Zac-Varghese Stephen Bain Adnan Sharif Srikanth Bellary Indranil Dasgupta |
| author_sort | Parijat De |
| collection | DOAJ |
| description | Abstract People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular disease. Slowing progression of kidney disease and reducing cardiovascular events can be achieved by a number of means including the targeting of blood pressure and the use of specific classes of drugs The use of Renin Angiotensin Aldosterone System (RAAS) blockade is effective in preventing or slowing progression of DKD and reducing cardiovascular events in people with type 2 diabetes, albeit differently according to the stage of DKD. However, emerging therapy such as non-steroidal selective mineralocorticoid antagonists (finerenone) is proven to lower blood pressure and further reduce the risk of progression of DKD and cardiovascular disease in people with type 2 diabetes. This consensus reviews current evidence and make recommendations for the use of finerenone in the management of diabetes kidney disease in the UK. |
| format | Article |
| id | doaj-art-95c1ec77939d4f6589458d7db7d84231 |
| institution | Kabale University |
| issn | 1471-2369 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nephrology |
| spelling | doaj-art-95c1ec77939d4f6589458d7db7d842312025-02-09T12:16:57ZengBMCBMC Nephrology1471-23692025-02-012611710.1186/s12882-025-03985-9Finerenone in the management of diabetes kidney diseaseParijat De0May T Khine1Andrew Frankel2Gabrielle Goldet3Debasish Banerjee4Rosa M Montero5Tahseen A Chowdhury6Damien Fogarty7Janaka Karalliedde8Ritwika Mallik9Dipesh C Patel10Mona Wahba11Peter Winocour12Sagen Zac-Varghese13Stephen Bain14Adnan Sharif15Srikanth Bellary16Indranil Dasgupta17Sandwell & West Birmingham NHS TrustSandwell & West Birmingham NHS TrustImperial College Healthcare NHS TrustImperial College Healthcare NHS TrustSt George’s Hospitals NHS Foundation TrustSt George’s Hospitals NHS Foundation TrustRoyal London HospitalBelfast Health and Social Care TrustKing’s College London and Guy’s and St Thomas HospitalUniversity College London Hospitals NHS Foundation TrustDepartment of Medicine, University College LondonSt Helier HospitalENHIDE, East and North Herts NHS TrustENHIDE, East and North Herts NHS TrustSwansea UniversityUniversity Hospitals Birmingham NHS Foundation TrustUniversity Hospitals Birmingham NHS Foundation TrustUniversity Hospitals Birmingham NHS Foundation TrustAbstract People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular disease. Slowing progression of kidney disease and reducing cardiovascular events can be achieved by a number of means including the targeting of blood pressure and the use of specific classes of drugs The use of Renin Angiotensin Aldosterone System (RAAS) blockade is effective in preventing or slowing progression of DKD and reducing cardiovascular events in people with type 2 diabetes, albeit differently according to the stage of DKD. However, emerging therapy such as non-steroidal selective mineralocorticoid antagonists (finerenone) is proven to lower blood pressure and further reduce the risk of progression of DKD and cardiovascular disease in people with type 2 diabetes. This consensus reviews current evidence and make recommendations for the use of finerenone in the management of diabetes kidney disease in the UK.https://doi.org/10.1186/s12882-025-03985-9DiabetesHypertensionAlbuminuriaDiabetic kidney diseaseFinerenoneACE inhibitors |
| spellingShingle | Parijat De May T Khine Andrew Frankel Gabrielle Goldet Debasish Banerjee Rosa M Montero Tahseen A Chowdhury Damien Fogarty Janaka Karalliedde Ritwika Mallik Dipesh C Patel Mona Wahba Peter Winocour Sagen Zac-Varghese Stephen Bain Adnan Sharif Srikanth Bellary Indranil Dasgupta Finerenone in the management of diabetes kidney disease BMC Nephrology Diabetes Hypertension Albuminuria Diabetic kidney disease Finerenone ACE inhibitors |
| title | Finerenone in the management of diabetes kidney disease |
| title_full | Finerenone in the management of diabetes kidney disease |
| title_fullStr | Finerenone in the management of diabetes kidney disease |
| title_full_unstemmed | Finerenone in the management of diabetes kidney disease |
| title_short | Finerenone in the management of diabetes kidney disease |
| title_sort | finerenone in the management of diabetes kidney disease |
| topic | Diabetes Hypertension Albuminuria Diabetic kidney disease Finerenone ACE inhibitors |
| url | https://doi.org/10.1186/s12882-025-03985-9 |
| work_keys_str_mv | AT parijatde finerenoneinthemanagementofdiabeteskidneydisease AT maytkhine finerenoneinthemanagementofdiabeteskidneydisease AT andrewfrankel finerenoneinthemanagementofdiabeteskidneydisease AT gabriellegoldet finerenoneinthemanagementofdiabeteskidneydisease AT debasishbanerjee finerenoneinthemanagementofdiabeteskidneydisease AT rosammontero finerenoneinthemanagementofdiabeteskidneydisease AT tahseenachowdhury finerenoneinthemanagementofdiabeteskidneydisease AT damienfogarty finerenoneinthemanagementofdiabeteskidneydisease AT janakakaralliedde finerenoneinthemanagementofdiabeteskidneydisease AT ritwikamallik finerenoneinthemanagementofdiabeteskidneydisease AT dipeshcpatel finerenoneinthemanagementofdiabeteskidneydisease AT monawahba finerenoneinthemanagementofdiabeteskidneydisease AT peterwinocour finerenoneinthemanagementofdiabeteskidneydisease AT sagenzacvarghese finerenoneinthemanagementofdiabeteskidneydisease AT stephenbain finerenoneinthemanagementofdiabeteskidneydisease AT adnansharif finerenoneinthemanagementofdiabeteskidneydisease AT srikanthbellary finerenoneinthemanagementofdiabeteskidneydisease AT indranildasgupta finerenoneinthemanagementofdiabeteskidneydisease |